Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene's Syndromic Test Detects 21 Targets for 19 Respiratory Viruses in Single Sample, Including COVID-19 and Flu

By LabMedica International staff writers
Posted on 07 Apr 2022

The world has turned its focus to living with COVID-19 endemically and relaxed social distancing and mask restrictions have created an environment for various respiratory viruses to circulate with ease. More...

Symptoms of COVID-19, such as coughing and fever, can also be a sign of other respiratory infections. A recent study showed that patients who contracted both COVID-19 and flu had more than double the risk of death, while the need for invasive medical ventilation jumped by four-fold. This makes testing critical for proper care as treatments can vary by infection type and to reduce the potential of co-infection. Now, a new test detects 21 targets for 19 respiratory viruses in single tube, including COVID-19 and flu.

Seegene, Inc.’s (Seoul, Korea) Allplex RV Master Assay can distinguish 21 targets for 19 different respiratory viruses, including COVID-19, flu, and common colds. Specifically, the assay can identify three genes of COVID-19, Flu A, Flu B, metapneumovirus, two types of respiratory syncytial virus, four types of parainfluenza virus, six types of adenovirus and three types of human rhinovirus. The syndromic test allows medical specialists to swiftly find out which viruses are making the patient sick with a single sample.

Seegene's independent clinical test recently conducted in Europe using the Allplex RV Master Assay on 1,928 people found that 16.5% (318 people) tested positive for respiratory viruses, excluding COVID-19. Of that figure, 6.9% (22 people) had contracted two or more viruses. The Allplex RV Master Assay has been designed in consideration of countries shifting policies to get everyday life back to normal. The Allplex RV Master Assay has received approval from Australia's Therapeutic Goods Administration and also achieved the European CE-IVD marking.

"Allplex RV Master Assay can detect respiratory viruses that can occur all-year round to simplify the diagnostic of the 'new normal' respiratory virus composition," said Dr. Tove Havnhøj Frandsen of Hospital of Southern Jutland/RenTov Consult, who led Seegene's clinical test in Europe. "The assay is expected to be well-utilized as winter approaches in Australia and South America and as the world turns to live with COVID-19 endemically."

Related Links:
Seegene, Inc.


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.